Text Size

NG PROMUS Stent System for the Treatment of Atherosclerotic Coronary Lesions

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Boston Scientific Corporation
ClinicalTrials.gov Identifier:
NCT01703000
First received: October 5, 2012
Last updated: March 19, 2013
Last verified: March 2013
History of Changes
  Purpose

NG PROMUS: A Prospective, Multicenter Trial to Assess the NG PROMUS Everolimus-Eluting Platinum Chromium Coronary Stent System (NG PROMUS Stent System) for the Treatment of Atherosclerotic Lesion(s)


Condition Intervention
Atherosclerosis
Coronary Artery Disease
 Device: Percutaneous coronary intervention (NG PROMUS)

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: NG PROMUS: A Prospective, Multicenter Trial to Assess the NG PROMUS Everolimus-Eluting Platinum Chromium Coronary Stent System (NG PROMUS Stent System) for the Treatment of Atherosclerotic Lesion(s)

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Boston Scientific Corporation:

Primary Outcome Measures:
  • Technical success rate [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 1 day ] [ Designated as safety issue: Yes ]
    Technical success is defined as successful delivery and deployment of the study stent to the target lesion, without balloon rupture or stent embolization, and post-procedure diameter stenosis of <30% assessed in 2 near-orthogonal projections with TIMI 3 flow in the target lesion, as visually assessed by the physician


Secondary Outcome Measures:
  • Target lesion revascularization (TLR) rate [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 1 day and at 30 days ] [ Designated as safety issue: No ]

    Target lesion revascularization is any ischemia-driven repeat percutaneous intervention, to improve blood flow, of the successfully treated target lesion or bypass surgery of the target vessel with a graft distally to the successfully treated target lesion. A TLR will be considered as ischemia-driven if the target lesion diameter stenosis is >/= 50% by QCA and there is presence of clinical or functional ischemia which cannot be explained by other coronary or graft lesions. Clinical or functional ischemia is any of the following:

    • The subject has a positive functional study corresponding to the area served by the target lesion.
    • The subject has ischemic ECG changes at rest in a distribution consistent with the target vessel.
    • The subject has ischemic symptoms referable to the target lesion. A TLR will be considered as ischemia-driven if the lesion diameter stenosis is >/= 70% by QCA even in the absence of clinical or functional ischemia.

  • Target lesion failure (TLF) rate [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 1 day and at 30 days ] [ Designated as safety issue: Yes ]
    Target lesion failure is any ischemia-driven revascularization of the target lesion, MI (Q-wave and non-Q-wave) related to the target vessel, or (cardiac) death. For the purposes of this protocol, if it cannot be determined with certainty whether the MI was related to the target vessel, it will be considered a TLF.

  • Target vessel revascularization (TVR) rate [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 1 day and at 30 days ] [ Designated as safety issue: No ]

    Target vessel revascularization is defined as a TLR or a TVR remote. Target vessel revascularization remote is any ischemia-driven repeat percutaneous intervention, to improve blood flow, or bypass surgery of not previously existing lesions diameter stenosis >/= 50% by QCA in the target vessel, excluding the target lesion. A TVR will be considered ischemia-driven if the target vessel diameter stenosis is >/= 50% by QCA and any of the following are present:

    • The subject has a positive functional study corresponding to the area served by the target vessel.
    • The subject has ischemic ECG changes at rest in a distribution consistent with the target vessel.
    • The subject has ischemic symptoms referable to the target vessel. A TVR will also be considered as ischemia-driven if the lesion diameter stenosis is >/=70% even in the absence of clinical or functional ischemia.

  • Target vessel failure (TVF) rate [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 1 day and at 30 days ] [ Designated as safety issue: Yes ]
    Target vessel failure is any ischemia-driven revascularization of the target vessel, MI (Q-wave and non-Q-wave) related to the target vessel or death related to the target vessel. For the purposes of this protocol, if it cannot be determined with certainty whether the MI or death was related to the target vessel, it will be considered a TVF.

  • Myocardial infarction (MI, Q-wave and non-Q-wave) rate [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 1 day and at 30 days ] [ Designated as safety issue: Yes ]
    MI will be defined according to the NG PROMUS Definition and the Universal Definition of MI with evidence pre-specified for i) Spontaneous, ii) PCI-related, iii) CABG related, and iv) autopsy evidence criteria.

  • Cardiac death rate [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 1 day and at 30 days ] [ Designated as safety issue: Yes ]

    Cardiac death is defined as death due to any of the following.

    • Acute MI
    • Cardiac perforation/pericardial tamponade
    • Arrhythmia or conduction abnormality
    • CVA through hospital discharge or CVA suspected of being related to the procedure
    • Death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery
    • Any death in which a cardiac cause cannot be excluded

  • Non-cardiac death rate [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 1 day and at 30 days ] [ Designated as safety issue: Yes ]

    Non-cardiac death is defined as a death not due to any of the following:

    • Acute MI
    • Cardiac perforation/pericardial tamponade
    • Arrhythmia or conduction abnormality
    • CVA through hospital discharge or CVA suspected of being related to the procedure
    • Death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery
    • Any death in which a cardiac cause cannot be excluded

  • All death rate [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 1 day and at 30 days ] [ Designated as safety issue: Yes ]
    Death is categorized as cardiac or non-cardiac deaths.

  • Cardiac death or MI rate [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 1 day and at 30 days ] [ Designated as safety issue: Yes ]
    Any cardiac death or MI event meeting the criteria defined for a cardiac death or MI.

  • All death or MI rate [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 1 day and at 30 days ] [ Designated as safety issue: Yes ]
    Any all-cause mortality event or MI meeting the criteria defined for any death or MI.

  • All death/MI/TVR rate [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 1 day and at 30 days ] [ Designated as safety issue: Yes ]
    Any event meeting the pre-specified criteria for any death, MI, or TVR.

  • Stent thrombosis rate (by Academic Research Consortium [ARC] definitions) [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 1 day and at 30 days ] [ Designated as safety issue: Yes ]

    Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guide catheter has been removed and the patient left the catheterization lab.

    Timing:

    • Acute stent thrombosis*: 0 24 hours after stent implantation
    • Subacute stent thrombosis*: >24 hours to 30 days after stent implantation
    • Late stent thrombosis: >30 days to 1 year after stent implantation
    • Very late stent thrombosis: >1 year after stent implantation * Acute/subacute can also be replaced by early stent thrombosis. Early stent thrombosis is 0 30 days.

    Stent thrombosis may be defined as:

    • Confirmed/definite
    • Probable
    • Possible

    Confirmed/Definite (is considered either angiographic confirmed or pathologic confirmed)


  • Clinical procedural success rate [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 1 day ] [ Designated as safety issue: Yes ]
    Clinical procedural success is post-procedure diameter stenosis <30% in 2 near-orthogonal projections with TIMI 3 flow in all target lesions, as visually assessed by the physician, without the occurrence of in-hospital MI, TVR, or cardiac death.

  • In-stent and in-segment percent diameter stenosis (%DS) [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 1 day ] [ Designated as safety issue: No ]
    As measured by angiography, the % diameter stenosis of the in-stent region and the in-segment region (including 5 mm proximal and distal).

  • In-stent and in-segment minimum lumen diameter (MLD) [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 1 day ] [ Designated as safety issue: No ]
    As measured by angiography, the minimum lumen diameter measured at the in-stent and the in-segment region (including 5 mm proximal and distal).

  • Acute gain [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 1 day ] [ Designated as safety issue: No ]
    Acute gain, as measured by angiographic core lab

  • Longitudinal stent deformation [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 1 day ] [ Designated as safety issue: No ]
    Longitudinal stent deformation, evidenced by longitudinal compression or elongation, as the result of crossing a newly deployed stent with a second device, (such as a balloon catheter, stent system or IVUS catheter), causing the second device to become caught on the stent when the second device is advanced or retracted.

  • Stent, vessel and lumen areas and volumes [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 1 day ] [ Designated as safety issue: No ]
    As measured by IVUS, the area and volume of the stent, vessel, and lumen.

  • Incomplete apposition [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 1 day ] [ Designated as safety issue: No ]
    Incomplete apposition rate, as measured by the IVUS core lab

  • Percent net volume obstruction [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 1 day ] [ Designated as safety issue: No ]
    The percentage of volume obstruction, as measured by the IVUS core lab.


Enrollment: 100
Study Start Date: November 2012
Study Completion Date: March 2013
Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: NG PROMUS stent
Single-arm treatment group receiving interventional NG PROMUS study stent
 Device: Percutaneous coronary intervention (NG PROMUS)
Interventional coronary artery stenting with NG PROMUS study stent.

Detailed Description:

To evaluate clinical and peri-procedural angiographic and intravascular ultrasound (IVUS) outcomes for the NG PROMUS Everolimus-Eluting Platinum Chromium Coronary Stent System (NG PROMUS Stent System) in the treatment of subjects with atherosclerotic lesion(s) ≤ 34 mm in length (by visual estimate) in native coronary arteries ≥ 2.50 mm to ≤ 4.0 mm in diameter (by visual estimate)

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Clinical Inclusion Criteria:

  1. Subject must be at least 18 years of age
  2. Subject (or legal guardian) understands the trial requirements and the treatment procedures and provides written informed consent before any trial-specific tests or procedures are performed
  3. Subject is eligible for percutaneous coronary intervention (PCI)
  4. Subject has symptomatic coronary artery disease with objective evidence of ischemia or silent ischemia
  5. Subject is an acceptable candidate for coronary artery bypass grafting (CABG)
  6. Subject is willing to comply with all protocol-required follow-up evaluation

Angiographic Inclusion Criteria:

  1. Target lesion(s) must be located in a native coronary artery with a visually estimated reference vessel diameter (RVD) ≥2.50 mm and ≤4.0 mm
  2. Target lesion(s) length must be ≤34 mm (by visual estimate)
  3. Target lesion(s) must have visually estimated stenosis ≥50% and <100% with thrombolysis in Myocardial Infarction (TIMI) flow >1 and one of the following (stenosis ≥70%, abnormal fractional flow reserve (FFR), abnormal stress test or imaging stress test, or elevated biomarkers) prior to procedure
  4. Coronary anatomy is likely to allow delivery of a study device to the target lesions(s)
  5. The first lesion treated must be successfully pre-dilated/pretreated Note: Successful pre-dilatation/pretreatment refers to dilatation with a balloon catheter of appropriate length and diameter, or pretreatment with directional or rotational coronary atherectomy, laser or cutting/scoring balloon with no greater than 50% residual stenosis and no dissection greater than National Heart, Lung, Blood Institute (NHLBI) type C.

Clinical Exclusion Criteria:

  1. Subject has clinical symptoms and/or electrocardiogram (ECG) changes consistent with acute ST elevation MI (STEMI)
  2. Subject has cardiogenic shock, hemodynamic instability requiring inotropic or mechanical circulatory support, intractable ventricular arrhythmias, or ongoing intractable angina
  3. Subject has received an organ transplant or is on a waiting list for an organ transplant
  4. Subject is receiving or scheduled to receive chemotherapy within 30 days before or after the index procedure
  5. Planned PCI (including staged procedures) or CABG after the index procedure
  6. Subject previously treated at any time with intravascular brachytherapy
  7. Subject has a known allergy to contrast (that cannot be adequately premedicated) and/or the trial stent system or protocol-required concomitant medications (e.g., platinum, platinum-chromium alloy, stainless steel, everolimus or structurally related compounds, polymer or individual components, all P2Y12 inhibitors, or aspirin)
  8. Subject has one of the following (as assessed prior to the index procedure):Other serious medical illness (e.g., cancer, congestive heart failure) with estimated life expectancy of less than 24 months; Current problems with substance abuse (e.g., alcohol, cocaine, heroin, etc.);Planned procedure that may cause non-compliance with the protocol or confound data interpretation
  9. Subject is receiving chronic (≥72 hours) anticoagulation therapy (i.e., heparin, coumadin) for indications other than acute coronary syndrome
  10. Subject has a platelet count <100,000 cells/mm3 or >700,000 cells/mm3
  11. Subject has a white blood cell (WBC) count < 3,000 cells/mm3
  12. Subject has documented or suspected liver disease, including laboratory evidence of hepatitis
  13. Subject is on dialysis or has baseline serum creatinine level >2.0 mg/dL (177µmol/L)
  14. Subject has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions
  15. Subject has had a history of cerebrovascular accident (CVA) or transient ischemic attack (TIA) within the past 6 months
  16. Subject has an active peptic ulcer or active gastrointestinal (GI) bleeding
  17. Subject has signs or symptoms of active heart failure (i.e., NYHA class IV) at the time of the index procedure
  18. Subject is participating in another investigational drug or device clinical trial that has not reached its primary endpoint
  19. Subject intends to participate in another investigational drug or device clinical trial within 12 months after the index procedure
  20. Subject with known intention to procreate within 12 months after the index procedure (women of child-bearing potential who are sexually active must agree to use a reliable method of contraception from the time of screening through 12 months after the index procedure)
  21. Subject is a woman who is pregnant or nursing (a pregnancy test must be performed within 7 days prior to the index procedure in women of child-bearing potential)

Angiographic Exclusion Criteria:

  1. Planned treatment of more than 3 lesions.
  2. Planned treatment of lesions in more than 2 major epicardial vessels
  3. Planned treatment of a single lesion with more than 1 stent
  4. Subject has 2 target lesions in the same vessel that are separated by less than 15 mm (by visual estimate)
  5. Target lesion(s) is located in the left main
  6. Target lesion(s) is located within 3 mm of the origin of the left anterior descending (LAD) coronary artery or left circumflex (LCx) coronary artery by visual estimate.
  7. Target lesion(s) is located within a saphenous vein graft or an arterial graft
  8. Target lesion(s) will be accessed via a saphenous vein graft or arterial graft
  9. Target lesion(s) with a TIMI flow 0 (total occlusion) or TIMI flow 1 prior to guide wire crossing
  10. Target lesion(s) treated during the index procedure that involves a complex bifurcation (e.g., bifurcation lesion requiring treatment with more than 1 stent)
  11. Target lesion(s) is restenotic from a previous stent implantation or study stent would overlap with a previous stent
  12. Subject has unprotected left main coronary artery disease (>50% diameter stenosis)
  13. Subject has been treated with any type of PCI (i.e., balloon angioplasty, stent, cutting balloon atherectomy) within 24 hours prior to the index procedure
  14. Thrombus, or possible thrombus, present in the target vessel (by visual estimate)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01703000

Locations
Australia, Western Australia
Fremantle Hospital
Fremantle, Western Australia, Australia, 6160
New Zealand
Mercy Angiography Unit, Ltd. Mercy Hospital
Auckland, New Zealand, 1003
Auckland City Hospital
Auckland, New Zealand, 1010
North Shore Hospital
Auckland, New Zealand, 1030
Ascot Angiography
Auckland, New Zealand, 1546
Christchurch
Christchurch, New Zealand, 8140
Middlemore Hospital
Otahuhu, New Zealand, 1640
Singapore
National Heart Center Singapore
Singapore, Singapore, 168752
National University Hospital Singapore
Singapore, Singapore, 119228
Sponsors and Collaborators
Boston Scientific Corporation
Investigators
Principal Investigator: John A Ormiston, MBChB, FRACP, FRACR Mercy Angiography Unit, Ltd. Mercy Hospital
  More Information

Additional Information:
Drug-eluting product information from Manufacturer  This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party: Boston Scientific Corporation
ClinicalTrials.gov Identifier: NCT01703000     History of Changes
Other Study ID Numbers: NG PROMUS Clinical Trial S2294
Study First Received: October 5, 2012
Last Updated: March 19, 2013
Health Authority: Singapore: Health Sciences Authority
Australia: Department of Health and Ageing Therapeutic Goods Administration
New Zealand: Medsafe - Medicines and Medical Devices Safety Authority

Keywords provided by Boston Scientific Corporation:
drug eluting coronary stent

Additional relevant MeSH terms:
Atherosclerosis
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Arteriosclerosis
 Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Heart Diseases

ClinicalTrials.gov processed this record on May 21, 2013